A1 receptor-mediated protection against amyloid beta-induced injury in human neuroglioma cells

Korean Journal of Physiology and Pharmacology

Volumn 11, Issue 2, 2007, Pages 37-43

  Cho, Yong Woon ^a   Jung, Hyun Ju ^a   Kim, Yong Keun ^a   Woo, Jae Suk ^a  

^a Pusan National University School of Medicine   (South Korea)

Author keywords

A1 receptor; Adenosine; Amyloid beta peptide; Apoptosis; Glial cell

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 5 HYDROXYDECANOIC ACID; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; ADENOSINE TRIPHOSPHATE; AMYLOID BETA PROTEIN; CASPASE 9; CYTOCHROME C; NUCLEOTIDE; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT;

APOPTOSIS; ARTICLE; ASTROCYTE; BRAIN MITOCHONDRION; CELL DAMAGE; CELL LEVEL; CELL VIABILITY; CONTROLLED STUDY; CYTOSOL; DRUG ACTIVITY; ENZYME ACTIVATION; GLIA CELL; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MITOCHONDRIAL PERMEABILITY; NEUROPROTECTION; PROTEIN SECRETION;

EID: 34249026635     PISSN: 12264512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Abramov AY, Canevari L, Duchen MR. Changes in intracellular calcium and glutathione in astrocytes as the primary mechanism of amyloid neurotoxicity. J Neurosci 23: 5088-5095, 2003
2. Anandatheerthavarada HK, Biswas G, Robin MA, Avadhani NG. Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol 161: 41-54, 2003
3. Andoh T, Ishiwa D, Kamiya Y, Echigo N, Goto T, Yamada Y. A1 adenosine receptor-mediated modulation of neuronal ATP-sensitive K channels in rat substantia nigra. Brain Res 1124: 55-61, 2006
4. Bachurin SO, Shevtsova EP, Kireeva EG, Oxenkrug GF, Sablin SO. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann N Y Acad Sci 993: 334-344, 2003
5. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976
6. Daly JW. Adenosine receptors: targets for future drugs. J Med Chem 25: 197-207, 1982
7. 1 adenosine receptor antagonist. Life Sci 140: 555-561, 1987
8. Inoue I, Nagase H, Kishi K, Higuti T. ATP-sensitive K+ channel in the mitochondrial inner membrane. Nature 352: 244-247, 1991
9. 3 adenosine receptor-selective antagonists. Neuropharmacol 36: 1157-1165, 1997
10. Kontush A. Amyloid-beta: an antioxidant that becomes a pro-oxidant and critically contributes to Alzheimer's disease. Free Radic Biol Med 31: 1120-1131, 2001
11. Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol 60: 619-642, 1998
12. Lassmann H, Bancher C, Breitschopf H, Wegiel J, Bobinski M, Jellinger K, Wisniewski HM. Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathol 89: 35-41, 1995
13. Lemasters JJ, Nieminen AL, Qian T, Trost LC, Elmore SP, Nishimura Y, Crowe RA, Cascio WE, Bradham CA, Brenner DA, Herman B. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta 1366: 177-196, 1998
14. Liu GS, Downey JM, Cohen MV. Adenosine, ischemia and pre-conditioning, In: Jacobson KA, Jarvis MF ed, Purinergic Approaches in Experimental Therapeutics. 1st ed. Wiley-Liss NY, p 153-172, 1997
15. Lyman GE, DeVincenzo JP. Determination of picogram amounts of ATP using the luciferin-luciferase enzyme system. Anal Biochem 21: 435-443, 1967
16. 6-cycloalkyladenosines. Potent, A1-selective adenosine agonists. J Med Chem 28: 1383-1384, 1985
17. Morgan DM. Tetrazolium (MTT) assay for cellular viability and activity. Methods Mol Biol 79: 179-183, 1998
18. Nagele RG, D'Andrea MR, Lee H, Venkataraman V, Wang HY. Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res 971: 197-209, 2003
19. Olah ME, Stiles GL. Adenosine receptor subtypes: characterization and therapeutic regulation. Ann Rev Pharmacol Toxicol 35: 581-606, 1995
20. Phillis JW. Adenosine, inosine, and oxypurines in cerebral ischemia. In: Schurr A, Rigor BM ed, Cerebral Ischemia and Resusscitation. 1st ed. CRC Press, Boca Raton, FL p 189-204, 1990
21. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 13: 1676-1687, 1993
22. Pike CJ, Walencewiez-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J Neurochem 64: 253-265, 1995
23. Rudolphi KA, Schubert P, Parkinson FE, Fredholm BB. Neuroprotective role of adenosine in cerebral ischaemia. Trends Pharmacol Sci 13: 439-445, 1992
24. Selkoe DJ. Amyloid beta-protein precursor: new clues to the genesis of Alzheimer's disease. Curr Opin Neurobiol 4: 708-716, 1994
25. Smale G, Nichols NR, Brady DR, Finch CE, Horton WE Jr. Evidence for apoptotic cell death in Alzheimer's disease. Exp Neurol 33: 225-230, 1995
26. Stiles GL. Adenosine receptors. J Biol Chem 267: 6451-6454, 1992
27. + channel openers? Trends Pharmacol Sci 20: 157-161, 1999
28. 2 adenosine receptors. Life Sci 39: 743-750, 1986
29. Von Lubitz DK, Diemer NH. Self-defense of the brain: adenosinergic strategies. In: Marangos PJ, Lal H ed, Emerging Strategies in Neuroprotection. Birkhauser, Boston, MA, p 151-186, 1990
30. Von Lubitz DK, Carter MF, Beenhakker M, Lin RC, Jacobson KA. Adenosine: a prototherapeutic concept in neurodegeneration. Ann N Y Acad Sci 765: 163-178, 1995a
31. Von Lubitz DK, Carter MF, Deutsch SI, Lin RC, Mastropaolo J, Meshulam Y, Jacobson KA. The effects of adenosine A3 receptor stimulation on seizures in mice. Eur J Pharmacol 275: 23-29, 1995b